Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Endometrial cancer
features abnormal growth of cells of the inner lining of the uterus with the potential to invade to other organs. Accumulating evidence suggests that aberrant expression of long non-coding RNA (lncRNA) may facilitate cancer progression. The aim of the present study was to identify the molecular mechanisms of the lncRNA known as
DLX6
antisense RNA 1 (DLX6-AS1) in
endometrial cancer
. Microarray-based analysis was utilized to predict expression profile and possible function pattern of
DLX6
-AS1 and
DLX6
in
endometrial cancer
, and their expression was quantified in 78 clinically obtained
endometrial cancer
tissues and also in cell lines. We next assessed the effects of
DLX6
-AS1 and
DLX6
on proliferation, invasion and apoptosis of
endometrial cancer
cells. A mouse xenograft model was established to confirm
DLX6
-AS1 functions and explore its underlying regulatory mechanisms in vivo.
DLX6
-AS1 and
DLX6
were highly expressed in
endometrial cancer
tissues and cells, and their silencing weakened the proliferative and invasive abilities of
endometrial cancer
cells and tumours, while promoting apoptosis. Mechanistic investigations indicated that
DLX6
-AS1 formed a triplex structure with
DLX6
via interaction with p300/E2F1 acetyltransferase. Thus, we find that functional up-regulation of
DLX6
-AS1 can promote
endometrial cancer
progression via a novel triplex mechanism that may prove to be great clinical significance for future treatments of
endometrial cancer
.
...
PMID:Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region. 3295 17
